Cited by 266Atherosclerosis and Cardiovascular DiseasesFatty Acid Research and HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.

The role of non-resolving inflammation in atherosclerosis

Open access

Kasikara, Canan, Doran, Amanda C., Cai, Bishuang, Tabas, Ira·2018·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

Non-resolving inflammation drives the development of clinically dangerous atherosclerotic lesions by promoting sustained plaque inflammation, large necrotic cores, thin fibrous caps, and thrombosis. Resolution of inflammation is not merely a passive return to homeostasis, but rather an active process mediated by specific molecules, including fatty acid-derived specialized pro-resolving mediators (SPMs). In advanced atherosclerosis, there is an imbalance between levels of SPMs and proinflammatory lipid mediators, which results in sustained leukocyte influx into lesions, inflammatory macrophage polarization, and impaired efferocytosis. In animal models of advanced atherosclerosis, restoration of SPMs limits plaque progression by suppressing inflammation, enhancing efferocytosis, and promoting an increase in collagen cap thickness. This Review discusses the roles of non-resolving inflammation in atherosclerosis and highlights the unique therapeutic potential of SPMs in blocking the progression of clinically dangerous plaques.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci97950

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes
Chistiakov, D. A., Bobryshev, Y. V., Nikiforov, N. G., Elizova, N. V., Sobenin, I. A., & Orekhov, A. N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.055 · Cited by 184
Retracted
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Atherosclerosis
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,880
Cytokine-mediated regulation of CXCR4 expression in human neutrophils
Nagase, H., Miyamasu, M., Yamaguchi, M., Imanishi, M., Tsuno, N. H., Matsushima, K., Yamamoto, K., Morita, Y., & Hirai, K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.711 · Cited by 4,713
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Self-citation
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,389
Untitled work
(1999) · PubMed · Cited by 2,062
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelká, K., van Vollenhoven, R., Sharp, J. T., Perez, J. L., & Spencer-Green, G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,786
Resolvins
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Resolvin E1 and protectin D1 activate inflammation-resolution programmes
Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007) · Nature · doi:10.1038/nature05877 · Cited by 1,219
Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing
Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
Clair, E. W. S., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E. C., Schiff, M. H., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,137
Macrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Self-citation
Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways
Serhan, C. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141647 · Cited by 1,020
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1
Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N. A., & Serhan, C. N. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042031 · Cited by 943
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Annexin A1 and glucocorticoids as effectors of the resolution of inflammation
Perretti, M., & D'Acquisto, F. (2009) · Nature Reviews Immunology · doi:10.1038/nri2470 · Cited by 915
Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081880 · Cited by 908
Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease
Haeggström, J. Z., & Funk, C. D. (2011) · Chemical Reviews · doi:10.1021/cr200246d · Cited by 875
A circadian clock in macrophages controls inflammatory immune responses
Keller, M., Mazuch, J., Abraham, U., Eom, G. D., Herzog, E. D., Volk, H.-D., Kramer, A., & Maier, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906361106 · Cited by 843
Inflammation and plaque vulnerability
Hansson, G. K., Libby, P., & Tabas, I. A. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12406 · Cited by 809
Self-citation
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family
Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C. J., Parmentier, M., Serhan, C. N., & Murphy, P. M. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001578 · Cited by 778
Resolvin D1 binds human phagocytes with evidence for proresolving receptors
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C., Yang, R., Petasis, N. A., & Serhan, C. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907342107 · Cited by 752
Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.
Clària, J., & Serhan, C. N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9475 · Cited by 703
Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins
Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., & Serhan, C. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4345 · Cited by 699
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis
Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., & Serhan, C. N. (2009) · Nature · doi:10.1038/nature08541 · Cited by 695
Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans
Libby, P., Lichtman, A. H., & Hansson, G. K. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.009 · Cited by 685
Circadian Gene Bmal1 Regulates Diurnal Oscillations of Ly6C hi Inflammatory Monocytes
Nguyen, K. D., Fentress, S. J., Qiu, Y., Yun, K., Cox, J. S., & Chawla, A. (2013) · Science · doi:10.1126/science.1240636 · Cited by 667
Infection regulates pro-resolving mediators that lower antibiotic requirements
Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T., Schmidt, B. A., & Serhan, C. N. (2012) · Nature · doi:10.1038/nature11042 · Cited by 664
Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation
Arita, M., Ohira, T., Sun, Y., Elangovan, S., Chiang, N., & Serhan, C. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3912 · Cited by 648
Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages
Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., & Brady, H. R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1663 · Cited by 638
Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis
Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., & Mehrabian, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025079 · Cited by 623
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators
Dalli, J., & Serhan, C. N. (2012) · Blood · doi:10.1182/blood-2012-04-423525 · Cited by 572
Resolvin D1 and Its Aspirin-triggered 17R Epimer
Sun, Y., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K. H., Campbell, E. L., Colgan, S. P., Petasis, N. A., & Serhan, C. N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609212200 · Cited by 559
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4 + CD25 + regulatory T cells is interleukin 10 dependent
Kearley, J., Barker, J. E., Robinson, D. S., & Lloyd, C. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051166 · Cited by 517
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis
Schrijvers, D. M., De Meyer, G. R. Y., Kockx, M. M., Herman, A. G., & Martinet, W. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000166517.18801.a7 · Cited by 509
Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases
Spite, M., Clària, J., & Serhan, C. N. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.006 · Cited by 464
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis
Spanbroek, R., Gräbner, R., Lötzer, K., Hildner, M., Urbach, A., Rühling, K., Moos, M. P. W., Kaiser, B., Cohnert, T. U., Wahlers, T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242716099 · Cited by 461
Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice
Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X.-P., Shaposhnik, Z., Funk, C. D., & Lusis, A. J. (2002) · Circulation Research · doi:10.1161/01.res.0000028008.99774.7f · Cited by 422
Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation
Serhan, C. N. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100322 · Cited by 421
Molecular action of methotrexate in inflammatory diseases.
Chan, E. S. L., & Cronstein, B. N. (2002) · Arthritis Research · doi:10.1186/ar419 · Cited by 419
Pathologic assessment of the vulnerable human coronary plaque
Kolodgie, F. D., Virmani, R., Burke, A. P., Farb, A., Weber, D. K., Kutys, R., Finn, A. V., & Gold, H. K. (2004) · Heart · doi:10.1136/hrt.2004.041798 · Cited by 415
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators
Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., & Chan, L. (2008) · The FASEB Journal · doi:10.1096/fj.08-112201 · Cited by 414
Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype
Titos, E., Rius, B., González-Périz, A., López-Vicario, C., Morán-Salvador, E., Martínez-Clemente, M., Arroyo, V., & Clària, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100225 · Cited by 412
An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques
Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12859 · Cited by 411
Self-citation
Identification of resolvin D2 receptor mediating resolution of infections and organ protection
Chiang, N., Dalli, J., Colas, R. A., & Serhan, C. N. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150225 · Cited by 397
The response‐to‐retention hypothesis of atherogenesis reinforced
Williams, K. J., & Tabas, I. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199810000-00012 · Cited by 395
Self-citation
5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.
Woods, J. W., Evans, J. F., Ethier, D., Scott, S., Vickers, P. J., Hearn, L., Heibein, J. A., Charleson, S. E., & Singer, I. I. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.6.1935 · Cited by 392
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice
Fredman, G., Kamaly, N., Spolitu, S., Milton, J., Ghorpade, D. S., Chiasson, R., Kuriakose, G., Perretti, M., Farokhzad, O. C., & Tabas, I. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1065 · Cited by 362
Self-citation
Mertk Receptor Mutation Reduces Efferocytosis Efficiency and Promotes Apoptotic Cell Accumulation and Plaque Necrosis in Atherosclerotic Lesions of Apoe −/− Mice
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., & Tabas, I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167197 · Cited by 357
Self-citation
A Novel Ligand of the Formyl Peptide Receptor
Walther, A., Riehemann, K., & Gerke, V. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80323-8 · Cited by 322
Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H., Gray, M., D’Acquisto, F., Buckingham, J. C., Perretti, M., & Flower, R. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903526 · Cited by 298
Shedding of the Mer Tyrosine Kinase Receptor Is Mediated by ADAM17 Protein through a Pathway Involving Reactive Oxygen Species, Protein Kinase Cδ, and p38 Mitogen-activated Protein Kinase (MAPK)
Thorp, E., Vaisar, T., Subramanian, M., Mautner, L., Blobel, C., & Tabas, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.263020 · Cited by 298
Self-citation
Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.
Maddox, J. F., & Serhan, C. N. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.137 · Cited by 295
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation
Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., & Serhan, C. N. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42545 · Cited by 292
Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation
El Kebir, D., Gjorstrup, P., & Filep, J. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206641109 · Cited by 289
Lipoxins, Aspirin-Triggered Epi-Lipoxins, Lipoxin Stable Analogues, and the Resolution of Inflammation: Stimulation of Macrophage Phagocytosis of Apoptotic Neutrophils In Vivo
Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N. A., Erwig, L., Rees, A. J., Savill, J., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032417.73640.72 · Cited by 287
The novel 13 S ,14 S ‐epoxy‐maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A 4 hydrolase (LTA 4 H), and shifts macrophage phenotype
Dalli, J., Zhu, M., Vlasenko, N. A., Deng, B., Haeggström, J. Z., Petasis, N. A., & Serhan, C. N. (2013) · The FASEB Journal · doi:10.1096/fj.13-227728 · Cited by 283
Annexin-1 and Peptide Derivatives Are Released by Apoptotic Cells and Stimulate Phagocytosis of Apoptotic Neutrophils by Macrophages
Scannell, M., Flanagan, M. B., deStefani, A., Wynne, K. J., Cagney, G., Godson, C., & MADERNA, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4595 · Cited by 282
Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors
Serhan, C. N., Krishnamoorthy, S., Recchiuti, A., & Chiang, N. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611109060629 · Cited by 281
Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis
Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T. E., & Serhan, C. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.044131 · Cited by 278
Living and dying for inflammation: neutrophils, eosinophils, basophils
Geering, B., Stoeckle, C., Conus, S., & Simon, H. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.04.002 · Cited by 276
Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor
Maddox, J. F., Hachicha, M., Takano, T., Petasis, N. A., Fokin, V. V., & Serhan, C. N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.6972 · Cited by 269
Activation of Lipoxin a4 Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation
Chiang, N., Fierro, I. M., Gronert, K., & Serhan, C. N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1197 · Cited by 262
MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis
Cai, B., Thorp, E. B., Doran, A. C., Sansbury, B. E., Daemen, M. J. A. P., Dorweiler, B., Spite, M., Fredman, G., & Tabas, I. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90520 · Cited by 262
Self-citation
Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci
Norling, L. V., Dalli, J., Flower, R. J., Serhan, C. N., & Perretti, M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.249508 · Cited by 260
MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation
Cai, B., Thorp, E. B., Doran, A. C., Subramanian, M., Sansbury, B. E., Lin, C., Spite, M. R., Fredman, G., & Tabas, I. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524292113 · Cited by 256
Self-citation
Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents
Dalli, J., Winkler, J. W., Colas, R. A., Arnardottir, H. H., Cheng, C.-Y. C., Chiang, N., Petasis, N. A., & Serhan, C. N. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.11.010 · Cited by 254
Expression of 5-lipoxygenase and leukotriene A 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability
Qiu, H., Gabrielsen, A., Agardh, H. E., Wan, M., Wetterholm, A., Wong, C., Hedin, U., Swedenborg, J., Hansson, G. K., Samuelsson, B. O., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602414103 · Cited by 249
Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice
Aiello, R. J., Bourassa, P.-A. K., Lindsey, S., Weng, W., Freeman, A., & Showell, H. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0302.105593 · Cited by 247
Airway Lipoxin A4 Generation and Lipoxin A4 Receptor Expression Are Decreased in Severe Asthma
Planagumà, A., Kazani, S. D., Marigowda, G., Haworth, O., Mariani, T. J., Israel, E., Bleecker, E. R., Curran‐Everett, D., ERZURUM, S. C., Calhoun, W. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-061oc · Cited by 247
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement
Hayhoe, R. P. G., Kamal, A. M., Solito, E., Flower, R. J., Cooper, D., & Perretti, M. (2005) · Blood · doi:10.1182/blood-2005-08-3099 · Cited by 239
Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma
Ball, R. Y., Stowers, E. C., Burton, J. H., Cary, N. R. B., Skepper, J. N., & Mitchinson, M. J. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05463-s · Cited by 236
Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis
Linton, M. F., Babaev, V. R., Huang, J., Linton, E. F., Tao, H., & Yancey, P. G. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0924 · Cited by 235
Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development.
Shen, J., Herderick, E. E., Cornhill, J. F., Zsigmond, E., Kim, H. S., Kühn, H., Guevara, J., & Chan, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119029 · Cited by 233
Mechanisms and consequences of efferocytosis in advanced atherosclerosis
Thorp, E., & Tabas, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209115 · Cited by 231
Self-citation
The molecular mechanisms of the thrombotic complications of atherosclerosis
Libby, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01965.x · Cited by 226
Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice
Viola, J. R., Lemnitzer, P., Jansen, Y., Csaba, G., Winter, C., Neideck, C., Silvestre-Roig, C., Dittmar, G., Döring, Y., Drechsler, M., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.309492 · Cited by 226
Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis
Kamaly, N., Fredman, G., Fojas, J. J. R., Subramanian, M., Choi, W. I., Zepeda, K., Vilos, C., Yu, M., Gadde, S., Wu, J., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b01114 · Cited by 221
Self-citation
Macrophage Phenotypes and Their Modulation in Atherosclerosis
Paoli, F. D., Staels, B., & Chinetti, G. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0621 · Cited by 214
Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC–MS/MS
Giera, M. A., Ioan‐Facsinay, A., Toes, R. E. M., Gao, F., Dalli, J., Deelder, A. M., Serhan, C. N., & Mayboroda, O. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.011 · Cited by 210
Role of Leukotriene B4Receptors in the Development of Atherosclerosis: Potential Mechanisms
Subbarao, K., Jala, V. R., Mathis, S., Suttles, J., Zacharias, W., Ahamed, J., Ali, H., Tseng, M. T., & Haribabu, B. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000110503.16605.15 · Cited by 210
Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement
Watson, R. W. G., Rotstein, O. D., Nathens, A. B., Parodo, J. C., & Marshall, J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.945 · Cited by 206
Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine Axis
Hachicha, M., Pouliot, M., Petasis, N. A., & Serhan, C. N. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1923 · Cited by 202
Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis
Hasturk, H., Abdallah, R., Kantarci, A., Nguyen, D., Giordano, N., Hamilton, J., & Van Dyke, T. E. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305324 · Cited by 199
Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B 4 synthesis by inhibiting a calcium-activated kinase pathway
Fredman, G., Özcan, L., Spolitu, S., Hellmann, J. L., Spite, M. R., Backs, J., & Tabas, I. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410851111 · Cited by 197
Self-citation
Resolvin E2 Formation and Impact in Inflammation Resolution
Oh, S. F., Dona, M., Fredman, G., Krishnamoorthy, S., Irimia, D., & Serhan, C. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103652 · Cited by 195
Defective Mer Receptor Tyrosine Kinase Signaling in Bone Marrow Cells Promotes Apoptotic Cell Accumulation and Accelerates Atherosclerosis
Ait-Oufella, H., Pouresmail, V., Simon, T., Blanc-Brude, O., Kinugawa, K., Merval, R., Offenstadt, G., Lesèche, G., Cohen, P. L., Tedgui, A., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.169078 · Cited by 187
Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice
White, P. J., Arita, M., Taguchi, R., Kang, J. X., & Marette, A. (2010) · Diabetes · doi:10.2337/db10-0054 · Cited by 185
Circulating and Dietary Omega‐3 and Omega‐6 Polyunsaturated Fatty Acids and Incidence of CVD in the Multi‐Ethnic Study of Atherosclerosis
Otto, M. C. D. O., Wu, J. H. Y., Baylín, A., Vaidya, D. M., Rich, S. S., Tsai, M. Y., Jacobs, D. R., & Mozaffarian, D. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000506 · Cited by 179
Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-α Secretion from Human T Cells
Ariel, A., Chiang, N., Arita, M., Petasis, N. A., & Serhan, C. N. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6266 · Cited by 175
From Asthma to Atherosclerosis — 5-Lipoxygenase, Leukotrienes, and Inflammation
Caterina, R. D., & Zampolli, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038190 · Cited by 173
Defective Phagocytosis of Apoptotic Cells by Macrophages in Atherosclerotic Lesions of ob/ob Mice and Reversal by a Fish Oil Diet
Li, S., Sun, Y., Liang, C., Thorp, E. B., Han, S., Jehle, A. W., Saraswathi, V., Pridgen, B. C., Kanter, J. E., Li, R., et al. (2009) · Circulation Research · doi:10.1161/circresaha.109.199570 · Cited by 173
Self-citation
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Aspirin-Triggered Lipoxin A4 Stimulates Alternative Activation of Microglia and Reduces Alzheimer Disease–Like Pathology in Mice
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome
Tardif, J., L’Allier, P. L., Ibrahim, R., Grégoire, J. C., Nozza, A., Cossette, M., Kouz, S., Lavoie, M.-A., Paquin, J., Brotz, T. M., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.937169 · Cited by 161
Impaired Cholesterol Metabolism and Enhanced Atherosclerosis in Clock Mutant Mice
Pan, X., Jiang, X., & Hussain, M. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002885 · Cited by 158
Role of IL-10 in Resolution of Inflammation and Functional Recovery after Peripheral Nerve Injury
Mietto, B. S., Kroner, A., Girolami, E. I., Santos-Nogueira, E., Zhang, J., & David, S. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2119-15.2015 · Cited by 152
Annexin A1 Counteracts Chemokine-Induced Arterial Myeloid Cell Recruitment
Drechsler, M., de Jong, R., Rossaint, J., Viola, J. R., Leoni, G., Wang, J. M., Grommes, J., Hinkel, R., Kupatt, C., Weber, C., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.305825 · Cited by 150
ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
Laguna-Fernandez, A., Checa, A., Carracedo, M., Artiach, G., Petri, M. H., Baumgartner, R., Forteza, M. J., Jiang, X., Andonova, T., Walker, M. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032801 · Cited by 141
Aspirin-Triggered Lipoxins Override the Apoptosis-Delaying Action of Serum Amyloid A in Human Neutrophils: A Novel Mechanism for Resolution of Inflammation
Kebir, D. E., József, L., Khreiss, T., Pan, W., Petasis, N. A., Serhan, C. N., & Filep, J. G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.616 · Cited by 139
Annexin A1 regulates intestinal mucosal injury, inflammation, and repair
Babbin, B. A., Laukoetter, M. G., Nava, P., Koch, S., Lee, W. Y., Capaldo, C. T., Peatman, E., Severson, E. A., Flower, R. J., Perretti, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.5035 · Cited by 134
Leukotriene Signaling in Atherosclerosis and Ischemia
Bäck, M. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6140-9 · Cited by 134
The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability
Petri, M. H., Laguna-Fernández, A., Gonzalez-Diez, M., Paulsson-Berne, G., Hansson, G. K., & Bäck, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvu224 · Cited by 125
Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)
Oikawa, S., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Sasaki, J., Hishida, H., Itakura, H., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.029 · Cited by 125
Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro
Chatterjee, B. E., Yona, S., Rosignoli, G., Young, R. E., Nourshargh, S., Flower, R. J., & Perretti, M. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405206 · Cited by 121
Aspirin‐triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E−/− mice
Petri, M. H., Laguna‐Fernandez, A., Arnardottir, H., Wheelock, C. E., Perretti, M., Hansson, G. K., & Bäck, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13707 · Cited by 120
CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis
Doran, A. C., Özcan, L., Cai, B., Zheng, Z., Fredman, G., Rymond, C. C., Dorweiler, B., Sluimer, J. C., Hsieh, J., Kuriakose, G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94735 · Cited by 113
Self-citation
Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets
Fredman, G., Dyke, T. E. V., & Serhan, C. N. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.209908 · Cited by 110
Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin
Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., Gjorstrup, P., & Kooistra, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.001 · Cited by 105
The obesity epidemic and its cardiovascular consequences
Behn, A., & Ur, E. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231406.84554.96 · Cited by 104
Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability
Fallahi‐Sichani, M., Flynn, J. L., Linderman, J. J., & Kirschner, D. E. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103298 · Cited by 99
Effect of interleukin 1β inhibition in cardiovascular disease
Qamar, A., & Rader, D. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328359b0a6 · Cited by 83
Overexpression of CRY1 protects against the development of atherosclerosis via the TLR/NF-κB pathway
Yang, L., Chu, Y., Wang, L., Wang, Y., Zhao, X., He, W., Zhang, P., Yang, X., Liu, X., Tian, L., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.001 · Cited by 81
The anti‐inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells
Zouki, C., Ouellet, S., & Filep, J. G. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.3.572 · Cited by 79
Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids?
Garbin, U., Baggio, E., Stranieri, C., Pasini, A., Manfro, S., Mozzini, C., Vallerio, P., Lipari, G., Merigo, F., Guidi, G. C., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs301 · Cited by 74
Influx of extracellular calcium is required for the membrane translocation of 5-lipoxygenase and leukotriene synthesis
Wong, A., Cook, M. N., Foley, J. J., Sarau, H. M., Marshall, P., & Hwang, S. M. (1991) · Biochemistry · doi:10.1021/bi00102a030 · Cited by 72
Activation of autophagy in macrophages by pro-resolving lipid mediators
Prieto, P., Rosales-Mendoza, C. E., TerrÓn, V., Toledano, V., Cuadrado, A., LÓpez-Collazo, E., Bannenberg, G., Martín-Sanz, P., FernÁndez-Velasco, M., & BoscÁ, L. (2015) · Autophagy · doi:10.1080/15548627.2015.1078958 · Cited by 71
Impaired Production and Diurnal Regulation of Vascular RvD n-3 DPA Increase Systemic Inflammation and Cardiovascular Disease
Colas, R. A., Souza, P. R., Walker, M. E., Burton, M., Zasłona, Z., Curtis, A. M., Marques, R. M., & Dalli, J. (2018) · Circulation Research · doi:10.1161/circresaha.117.312472 · Cited by 71
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome
Gaztañaga, J., Farkouh, M. E., Rudd, J. H. F., Brotz, T. M., Rosenbaum, D. H., Mani, V., Kerwin, T. C., Taub, R. A., Tardif, J., Tawakol, A. A., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.027 · Cited by 68
A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease
Assimes, T. L., Knowles, J. W., Priest, J. R., Basu, A., Borchert, A., Volcik, K. A., Grove, M. L., Tabor, H. K., Southwick, A. M., Tabibiazar, R., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.003 · Cited by 49
Nutrigenetic Disruption of Inflammation-Resolution Homeostasis and Atherogenesis
Merched, A. J., Serhan, C. N., & Chan, L. (2011) · Lifestyle Genomics · doi:10.1159/000326890 · Cited by 40
The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective
Wittwer, J., Bayer, M., Mosandl, A., Muntwyler, J., & Hersberger, M. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.103 · Cited by 39
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
MC-12, an Annexin A1-Based Peptide, Is Effective in the Treatment of Experimental Colitis
Ouyang, N., Zhu, C., Zhou, D., Nie, T., Go, M. F., Richards, R. J., & Rigas, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041585 · Cited by 33

Flagged first, then by citations

1 of the 135 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

10.1161/CIRCULATIONAHA.117 · DOI

Sorted by citations

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Self-citation
Efferocytosis in health and disease
Doran, A. C., Yurdagul, A., & Tabas, I. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0240-6 · Cited by 1,066
Self-citation
The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 760
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I. A., & Tao, W. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 544
Self-citation
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499

See all 266

Authors: Kasikara, C., Doran, A. C., Cai, B., & Tabas, I.
Affiliations: Columbia University (US)
ORCID: Doran, Amanda C.
Cai, Bishuang
Tabas, Ira
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2018-07-02
Volume: 128
Issue: 7
Pages: 2713-2723
ISSN: 0021-9738 (ISSN-L)
1558-8238
DOI: 10.1172/jci97950
PMC: PMC6025992
OpenAlex: W2809703637
Cited by: 266
References: 135
Citations by year: 2026: 14 · 2025: 27 · 2024: 28 · 2023: 37 · 2022: 43 · 2021: 46 · 2020: 39 · 2019: 25 · 2018: 7
FWCI: 2.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: American Heart Association (17FTF33660643, 15POST25620024)
National Institutes of Health
National Heart, Lung, and Blood Institute (R01HL132412, R01HL127464, P01HL087123, R01HL075662, T32HL120826)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: nonresolving inflammation, atherosclerosis, specialized pro-resolving mediators, inflammation resolution, atherosclerotic plaque, necrotic core, fibrous cap, thrombosis, macrophage polarization, efferocytosis, leukocyte influx, lipid mediators, plaque progression
MeSH terms: Animals, Humans, Inflammation, Models, Cardiovascular, Signal Transduction, Disease Progression, Inflammation Mediators, Atherosclerosis, Lipid Metabolism, Plaque, Atherosclerotic, Lipoxygenases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of non-resolving inflammation in atherosclerosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks